Here Are the Most Damning Parts of Apple's Blockbuster Lawsuit Against Qualcomm
Qualcomm has been abusing its monopoly power in the baseband market for years, according to Apple.
IBM Finally Turns the Corner
The multiyear earnings decline will end this year as Big Blue's transformation gains momentum.
What Is Bank of America’s Cost of Capital?
This is a fundamental concept that bank investors should be aware of.
Donald Trump's Corporate Tax Reforms Could Be Great for M&A but Terrible for Jobs
More money for corporate America doesn't mean more jobs.
Silencers for all and universal concealed carry are just two of the changes the new president could propose.
These five video games each have warning signs that suggest they might fail to meet expectations.
Here are five things to do before jumping into a virtual reality investment.
Could a buyout be on the horizon? Maybe, but that may not mean the stock bounce investors are expecting.
Both sides of the business are at major risk.
Can’t decide between a traditional IRA and a Roth? Here are a few points to consider.
The next "Battlefield" entry is likely more than two years out. That could actually be good for investors.
Embraer stock sank again in 2016, but it's already bouncing back. New products arriving next year will offer even more upside.
The company spent big money to grow, and it's possible that it's not going to be able to hold onto what it paid for.
The beloved brew is big business.
Wells Fargo tells investors to enjoy their recent 10% profit -- because it's all they're going to get.
Comcast has taken the wraps off the first entry in its upcoming Universal Monsters movie franchise, but its plans for an expanded universe could prove overly ambitious.
Fresh off being sued by the FTC for anti-competitive practices, Qualcomm is now facing another lawsuit from Apple.
The natural gas pipeline giant expects a strong year, but it will be rough as it faces tough comparable results while seeking to set new records.
These three growth stocks are cheap now, but they might not stay cheap for much longer.
The longer you let your money compound, the bigger it can grow.
That's a lot of money hanging in the balance.
Rumors that the company could be an acquisition target caused shares to spike on Monday.
Let's see how one of the best biotech stocks of 2016 stacks up to the pharmaceutical giant from Switzerland.